Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 9/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 8/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | HTR2B | P41595 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18591747 | 0.85 | DRD4 (0.41) | NCF1DRD4HRH3HRH1DRD2 | |
| SCHEMBL23664608 | 0.81 | HRH3 (0.41) | HRH3HRH1DRD2 | |
| SCHEMBL23664609 | 0.81 | SMN1; SMN2 (0.45) | ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL18591772 | 0.79 | SLC6A2 (0.40) | DRD4HRH3HRH1DRD2HTR2A | |
| SCHEMBL20325157 | 0.76 | HRH3 (0.54) | DRD4HRH3DRD2ALDH1A1MAPT | |
| SCHEMBL14438329 | 0.76 | NCF1 (0.65) | NCF1ALDH1A1GAAMAPT | |
| SCHEMBL22419324 | 0.74 | POLB (0.43) | NCF1DRD4HRH3HRH1DRD2 | |
| SCHEMBL2238765 | 0.73 | NCF1 (0.51) | NCF1ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL8351016 | 0.72 | DRD2 (0.44) | DRD4HRH3HRH1DRD2HTR2A | |
| SCHEMBL26972342 | 0.71 | GBA2 (0.36) | ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | NCF1 1994/4885DRD4 4462/4885HRH3 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.